全球下一代RNA定序市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

全球下一代RNA定序）市場規模預計將從2025年的52.8億美元成長至2034年的224.7億美元，2026年至2034年的複合年成長率（CAGR）為17.46%。隨著下一代RNA定序在轉錄組分析、基因表現分析和高級生物學研究中的重要性日益凸顯，該市場正在不斷擴張。 RNA定序有助於研究人員研究轉錄物、可變剪接、基因融合和其他分子特性，從而支持基因組學、藥物發現和精準醫療等領域的應用。近期市場估算與預測顯示，在生命科學領域研究活動的活性化和定序技術的普及推動下，基於NGS的RNA次世代定序定序將呈現強勁成長。

定序平台、樣品製備技術、生物資訊學和計算分析的進步推動了市場需求。製藥和生物技術公司正在利用RNA定序技術闡明疾病機制、識別生物標記並支持療法的開發。學術和臨床研究也促進了這項技術的廣泛應用，因為研究人員對更詳細的分子資訊的需求日益成長。定序與人工智慧（AI）和先進分析技術的結合將進一步提高對複雜轉錄組資料集的解讀能力，並實現更有效率的研究工作流程。

未來前景與定序成本的降低、準確性和通量的提高以及轉錄組資訊應用範圍的擴大密切相關。研究人員預計將擴大將RNA定序與其他基因組分析和多體學技術相結合，以獲得更廣泛的生物學見解。單細胞轉錄組學和空間轉錄組學的進步可能為定序提供者和分析平台帶來更多機會。隨著精準醫療和分子研究的不斷發展，新一代RNA定序有望繼續成為理解基因活性和生物變異的關鍵技術。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面而實用的見解。每份報告都包含幾個關鍵組成部分，旨在讓您全面了解市場環境：

市場概覽：本節提供清晰的市場概覽，包括關鍵定義、分類和當前產業格局。

市場動態：對影響市場成長的主要促進因素、阻礙因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本預測是基於特定預測期內的市場規模和成長模式數據。本節結合歷史趨勢、當前市場狀況和定量分析，揭示未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球下一代RNA定序市場：按產品和服務分類

• 市場分析、洞察與預測
• 耗材（萃取純化試劑盒、樣品製備盒、定序試劑及流動池等）
• 裝置
• 服務（RNA定序、生物資訊學和數據分析）

第5章：全球下一代RNA定序市場：依工作流程分類

• 市場分析、洞察與預測
• 定序預處理
• 定序
• 數據分析

第6章：全球下一代RNA定序市場：按應用領域分類

• 市場分析、洞察與預測
• 藥物發現與開發（腫瘤學、感染疾病及其他）
• 臨床診斷
• 其他

第7章 全球下一代RNA定序市場：依最終用途分類

• 市場分析、洞察與預測
• 學術研究機構
• 製藥和生物技術公司
• 醫院和診所
• 其他

第8章 全球下一代RNA定序市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 中國
  • 日本
  • 韓國
  • 印度
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Illumina Inc
  • Thermo Fisher Scientific Inc
  • Merck KGaA
  • QIAGEN NV
  • Pacific Biosciences Of California Inc
  • Oxford Nanopore Technologies Ltd
  • Agilent Technologies Inc
  • BGI Group
  • Roche Holding AG
  • Revvity Inc
  • Eurofins Scientific
  • Bio-Rad Laboratories Inc
  • Takara Bio Inc
  • Hamilton Company
  • Macrogen

The global next-generation RNA sequencing market size is expected to reach USD 22.47 Billion in 2034 from USD 5.28 Billion in 2025, growing at a CAGR of 17.46% during 2026-2034.This market is expanding as next-generation RNA sequencing becomes increasingly important for transcriptome analysis, gene-expression profiling, and advanced biological research. RNA sequencing can help researchers study transcripts, alternative splicing, gene fusions, and other molecular characteristics, supporting applications across genomics, drug discovery, and precision medicine. Recent market estimates project strong growth in NGS-based RNA sequencing, supported by increasing research activity and the broader use of sequencing technologies in life sciences.

Demand is being supported by improvements in sequencing platforms, library-preparation technologies, bioinformatics, and computational analysis. Pharmaceutical and biotechnology companies are using RNA-sequencing approaches to investigate disease mechanisms, identify biomarkers, and support therapeutic development. Academic and clinical research is also contributing to adoption as researchers require increasingly detailed molecular information. The integration of sequencing with artificial intelligence and advanced analytics can further improve the interpretation of complex transcriptomic datasets and support more efficient research workflows.

Future prospects are linked to declining sequencing costs, improvements in accuracy and throughput, and the expanding application of transcriptomic information. Researchers are expected to increasingly combine RNA sequencing with other genomic and multi-omics approaches to obtain broader biological insights. Advances in single-cell and spatial transcriptomics can create additional opportunities for sequencing providers and analytical platforms. As precision medicine and molecular research continue developing, next-generation RNA sequencing is expected to remain an important technology for understanding gene activity and biological variation.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product & Service

• Consumables (Extraction & Purification Kits, Library Preparation Kits, Sequencing Reagents & Flow Cells, Others)
• Instruments
• Service (RNA-Sequencing, Bioinformatics & Data Analysis)

By Workflow

• Pre-Sequencing
• Sequencing
• Data Analysis

By Application

• Drug Discovery & Development (Oncology, Infectious Diseases, Others)
• Clinical Diagnostics
• Others

By End Use

• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Hospitals & Clinics
• Others

COMPANIES PROFILED

• Illumina Inc., Thermo Fisher Scientific Inc., Merck KGaA, QIAGEN N.V., Pacific Biosciences of California Inc., Oxford Nanopore Technologies Ltd., Agilent Technologies Inc., BGI Group, Roche Holding AG, Revvity Inc., Eurofins Scientific, Bio-Rad Laboratories Inc., Takara Bio Inc., Hamilton Company, Macrogen

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL NEXT GENERATION RNA SEQUENCING MARKET: BY PRODUCT & SERVICE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product & Service
• 4.2. Consumables (Extraction & Purification Kits, Library Preparation Kits, Sequencing Reagents & Flow Cells, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Service (RNA-Sequencing, Bioinformatics & Data Analysis) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL NEXT GENERATION RNA SEQUENCING MARKET: BY WORKFLOW 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Workflow
• 5.2. Pre-Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Data Analysis Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL NEXT GENERATION RNA SEQUENCING MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Drug Discovery & Development (Oncology, Infectious Diseases, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Clinical Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL NEXT GENERATION RNA SEQUENCING MARKET: BY END USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End Use
• 7.2. Academic & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Pharmaceutical & Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL NEXT GENERATION RNA SEQUENCING MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product & Service
  • 8.2.2 By Workflow
  • 8.2.3 By Application
  • 8.2.4 By End Use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product & Service
  • 8.3.2 By Workflow
  • 8.3.3 By Application
  • 8.3.4 By End Use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Spain
  • 8.3.10 Russia
  • 8.3.11 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product & Service
  • 8.4.2 By Workflow
  • 8.4.3 By Application
  • 8.4.4 By End Use
  • 8.4.5 China
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 India
  • 8.4.9 Australia
  • 8.4.10 South East Asia
  • 8.4.11 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product & Service
  • 8.5.2 By Workflow
  • 8.5.3 By Application
  • 8.5.4 By End Use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product & Service
  • 8.6.2 By Workflow
  • 8.6.3 By Application
  • 8.6.4 By End Use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL NEXT GENERATION RNA SEQUENCING INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Illumina Inc
  • 10.2.2 Thermo Fisher Scientific Inc
  • 10.2.3 Merck KGaA
  • 10.2.4 QIAGEN N.V
  • 10.2.5 Pacific Biosciences Of California Inc
  • 10.2.6 Oxford Nanopore Technologies Ltd
  • 10.2.7 Agilent Technologies Inc
  • 10.2.8 BGI Group
  • 10.2.9 Roche Holding AG
  • 10.2.10 Revvity Inc
  • 10.2.11 Eurofins Scientific
  • 10.2.12 Bio-Rad Laboratories Inc
  • 10.2.13 Takara Bio Inc
  • 10.2.14 Hamilton Company
  • 10.2.15 Macrogen